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Sotrovimab is a new therapeutic agent to attenuate
COVID-19. It is considered a welcome pharmaceutical preparation in light of SARS-CoV-2 variants, such
as Omicron. Some other monoclonal antibody medications have low effectiveness at blocking Omicron’s
SARS-CoV-2 cell access. Sotrovimab fills an important therapeutic niche for victims of Omicron infection and is indicated for anyone with medical contraindications to vaccines, persons with serious comorbidities, and immunocompromised persons with
suboptimal response to vaccines, and it may be especially helpful with the emergence of variant viral
infections that evade vaccine- or illness-derived immunity.[1, 2] Sotrovimab reduces the risk of disease
progression among high-risk patients with mild-tomoderate COVID-19.[3] Sotrovimab may also reduce
the percentage of patients who require oxygen.[4] It
seems that sotrovimab is a better choice for dealing
with severe or non-severe COVID-19 patients.[5] Hopefully, it will provide high efficacy to patients with
early COVID-19, minimizing hospitalizations, morbidity, mortality, and/or healthcare system overload.
On May 26, 2021, this monoclonal antibody therapy
received emergency use authorization, which allows
medical personnel to administer sotrovimab. This
pharmaceutical binds to a preserved epitope on the
spike protein of SARS-CoV-2. Its exact mechanism of
action is unknown, but it appears to prevent membrane fusion after the virus binds to the angiotensinconverting enzyme-2 receptor, thus preventing cell en-
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try by the virus. Prescribed only early in mild to moderate COVID-19 disease, it is for patients over age 12
years, weighing at least 40 kg. Recipients should be
those who test positive for SARS-CoV-2 and are at high
risk of progressing to severe complications and/or hospitalization.[6, 7] It is delivered by a single 500 mg intravenous infusion.[2]
Monoclonal antibodies may be associated with worse
clinical outcomes when provided to sick patients with
serious COVID-19 conditions requiring high-flow oxygen or mechanical ventilation. Sotrovimab is to be dispensed in a setting where hypersensitivity reactions,
such as anaphylaxis, can be safely managed. Clinical
status is monitored during the infusion and ought to
be observed for at least one hour afterward.[2]
Sotrovimab can overcome viral replication and be directed against receptor-binding domain epitopes that
are conserved among SARS-CoV-2 variants and other
sarbecoviruses. Hopefully, sotrovimab will remain
therapeutically active as SARS-CoV-2 Omicron continues to evolve and for infections from the current
wave of illness. The drug concentration required to diminish viral replication by half was about three times
higher for Omicron than for certain other coronavirus
variants.[8] Although the neutralizing activity of sotrovimab against Omicron is present, the loss of activity of
some other monoclonal antibody drugs remains a concern; therefore the development of even newer monoclonal antibody modalities is needed.
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